Why InterMune (ITMN) Stock Is Gaining Today

NEW YORK (TheStreet) -- InterMune (ITMN) shares continue to climb on heavy volume Tuesday, up 0.2% to $73, after the company agreed to be bought by Swiss pharmaceutical company Roche for $8.3 billion.

See what Jim Cramer thinks of Roche's bid for InterMune:


WATCH: More market update videos on TheStreet TV | More videos from Jim Cramer



More than 12.5 million shares have been traded so far today, more than six times its three-month daily average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ITMN Chart ITMN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000